NADOX

Owner

Goods & Services

Antibiotic preparations relating to doxorubicin; chemotherapeutics relating to doxorubicin; pharmaceutical preparations for the treatment of tumours relating to doxorubicin; pharmaceutical preparations for chemical disorder treatment relating to doxorubicin; pharmaceutical agents affecting sensory organs relating to doxorubicin; pharmaceutical agents affecting metabolism relating to doxorubicin; pharmaceutical agents affecting peripheral nervous system relating to doxorubicin; cardiovascular pharmaceutical preparations relating to doxorubicin; pharmaceutical preparations and compositions for the treatment and prevention of cancer relating to doxorubicin; pharmaceutical preparations and substances for the prevention of cancer relating to doxorubicin; biopharmaceuticals for the treatment of cancer relating to doxorubicin; biological preparations for the treatment of cancer relating to doxorubicin; pharmaceutical preparations for the treatment of cancer relating to doxorubicin; pharmaceutical preparations acting on the central nervous system relating to doxorubicin; analgesic preparations relating to doxorubicin; antibiotics relating to doxorubicin; pharmaceutical preparations for the treatment and prevention of cancer in respiratory organs relating to doxorubicin; anti-cancer preparations relating to doxorubicin